Homepage » Personnel » Faculty Members » Pharmaceutical Technology » Moira Symillidou

Moira Symillidou

Associate Professor of Biopharmaceutics and Pharmacokinetics



  • B. Pharm. National and Kapodistrian University of Athens (1982)
  • Ph.D in Biopharmaceutics and Pharmacokinetics, National and Kapodistrian University of Athens (1987)


  • Undergraduate courses/labs: Biopharmaceutics and Pharmacokinetics I, Biopharmaceutics and Pharmacokinetics II, Biopharmaceutics and Pharmacokinetics (Laboratory Work)
  • Graduate courses: Advanced Biopharmaceutics and Pharmacokinetics, Statistical Methods and Applications in Pharmaceutical Sciences

Research topics

  • Theoretical Pharmacokinetics (focus on Absorption analysis)
  • Bioequivalence (Absorption rate and extent metrics, Highly Variable Drugs, Narrow Therapeutic Index Drugs)
  • In vitro Dissolution and Permeability studies. In vivo absorption studies. In vitro-in vivo correlations.


  • Research Fellow, IRT (Institut de Recherche Thérapeutique et Pharmacologique Clinique), Université René-Descartes, Hôpital Cochin, Paris (4/1989-1/1990)
  • Member of the Advisory Committee for the MSc program in Clinical Pharmacy (1994-2002)
  • Member of the Committee for Undergraduate Studies of the Faculty of Pharmacy, University of Athens (1996-1999)

Recent publications

  • Canine versus in vitro data for predicting input profiles of L-sulpiride after oral administration. N. Fotaki, M. Symillides, C. Reppas. Eur. J. Pharm. Sci., 26, 324-333 (2005)
  • Novel Scaled bioequivalence limits with levelling-off properties. J. Kytariolos, V. Karalis, Ρ. Macheras, Μ. Symillides. Pharm. Res., 23, 2657-2664 (2006)
  • Comparison of the reference scaled bioequivalence semi-replicate method with other approaches: Focus on human exposure to drugs. V. Karalis, M. Symillides, P. Macheras. Eur. J. Pharm. Sci., 38, 55-63 (2009)
  • Novel methods to assess bioequivalence. V. Karalis, M. Symillides, P. Macheras. Expert Opin Drug Metab Toxicol, 7, 79–88 (2011)
  • On the leveling-off properties of the new bioequivalence limits for highly variable drugs of the EMA guideline. V. Karalis, M. Symillides, P. Macheras. Eur. J. Pharm. Sci., 44, 497-505 (2011)
  • Bioequivalence of highly variable drugs: A comparison of the newly proposed regulatory approaches by FDA and EMA. V. Karalis, M. Symillides, P. Macheras. Pharm. Res., 29, 1066-1077 (2012)
  • Luminal lipid phases after administration of a triglyceride solution of danazol in the fed state and their contribution to the flux of danazol across Caco-2 cell monolayers. M. Vertzoni, C. Markopoulos, M. Symilllides, C. Goumas, G. Imanidis, C. Reppas. Mol. Pharmaceutics, 9, 1189-1198 (2012)


Moira Symillidou
Division of Pharmaceutical Technology
Faculty of Pharmacy
National and Kapodistrian University of Athens
Panepistimiopolis, 157 71 Zografou
Tel: + 30 210 727-4675
Fax: + 30 210 727-4027
E-mail: simillidou[at]pharm.uoa[dot]gr